Dexmedetomidine and Propofol Use for Palliative Sedation Therapy (PST) in Pediatric Oncology: A Ten-Year Review (GP750)
Andrea Cuviello,Melisa Pasli,Doralina Anghelescu,Liza-Marie Johnson,Justin Baker
DOI: https://doi.org/10.1016/j.jpainsymman.2022.04.141
IF: 5.576
2022-05-17
Journal of Pain and Symptom Management
Abstract:Outcomes 1. Discuss the characteristics of pediatric oncology patients who receive palliative sedation therapy 2. Highlight the use of dexmedetomidine in palliative sedation therapy for pediatric oncology patients at the end of life Importance During the end of life (EOL), some children experience extensive suffering, both physically and existentially, and attempts to control their symptoms with traditional symptom-directed agents may be unsuccessful. Palliative sedation therapy (PST) can help relieve suffering at the EOL for children with cancer, yet little is known about pediatric patients needing PST. Objective(s) Describe the characteristics of pediatric oncology patients needing PST at the EOL, identify the refractory symptoms experienced by patients at the EOL necessitating PST, and assess the timing of initiation of PST in regard to the documented time of death. Method(s) A retrospective review was completed for pediatric oncology patients who needed PST at St. Jude Children's Research Hospital between April 1, 2011, and January 1, 2021. Data collected included demographics, disease characteristics, EOL characteristics, and medications for PST and symptom management. Results Of 24 study participants, 83% (n = 20) received dexmedetomidine, 12.5% (n = 3) received propofol, and 4.2% (n = 1) received both for PST. The most common diagnosis of patients receiving PST was acute leukemia (37.5%), followed by sarcomas (46%). All patients were followed by the palliative care team and two thirds (66.6%, n = 16) by the pain management service; 79% (n = 19) were enrolled in hospice, and 98.5% (n = 23) had Physician Orders for Scope of Treatment in place prior to PST initiation. Pain was the most common refractory symptom leading to PST initiation (33.3%, n = 8), followed by dyspnea (12.5%), neuroagitation (16.7%), or some combination of these three symptoms. PST was initiated most commonly 2.5 days (mean 8.9 days) before death. A third of deaths occurred in the ICU (33.3%, n = 8). Conclusion(s) Our findings suggest that dexmedetomidine is effective as first line for PST for patients at the EOL with refractory symptoms. Impact The role of dexmedetomidine in PST protocols should further be validated with prospective studies.
medicine, general & internal,clinical neurology,health care sciences & services